Ali KUTLUCAN, Şevket Ercan TUNÇ, Davut BALTACI, Mehmet ŞAHİN, Mustafa ÖZŞAHİN, Recep SÜTÇÜ, Harun SÜSLÜ, MEHMET FATİH ERMİŞ

Serum levels of TNF-α and osteoprotegerin and bone mineral density in patients with Behçet’s Disease

Amaç: Behçet hastalığı (BH)’nın doğal seyri sırasında ya da kullanılan ilaçlara bağlı olarak osteoporoz gelişebilir. Çalışmanın amacı BH’nda osteoprotegerin ve tümor nekroz faktör (TNF-α) düzeyleri ve bunlar arasındaki korelasyonu araştırmaktır. Gereç ve yöntem: Çalışmaya, hasta grubu ve kontrol grubu olarak iki grup alındı. TNF-α, osteoprotegerin, osteokalsin, sedimantasyon, CRP, idrar kreatin ve deoksipridinolin düzeyleri ile beraber kemik mineral dansitometrisi (KMD) ölçüldü ve iki grup karşılaştırıldı. Bulgular: Çalışma grubuna 41 hasta, kontrol grubuna 36 hasta alındı. Çalışma ve kontrol grubunun yaş ortalaması sırasıyla 42.26±11.64 ve 41.66±70.99 bulundu. Vücut kitle indeksi yönünden iki grup arasında fark bulunmadı. TNF-α (p

Behçet hastalarında serum TNF- α ve osteoprotegerin düzeyi ve kemik kitle yoğunluğu

Objectives: Osteoporosis is commonly developed due to natural course of Behçet’s disease (BD) and therapeutic agents. It was aimed to investigate levels of osteoprotegerin and TNF-α (tumor necrosis factor), and bone mineral density (BMD) and correlation between them in BD. Materials and methods: The study included two groups as the study and the control group. Serum levels of TNF-α, osteoprotegerin, osteocalcine, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and urinary creatinine and deoxypyridinoline along with BMD level were evaluated and compared. Correlation between TNF-α and osteoprotegerin level was investigated. Results: The study enrolled 41 BD patients and 36 agedmatched control subjects. Mean age was 42.26±11.64 and 41.66±70.99, in the study and control groups, respectively. There was no significant difference in body mass index (BMI) of subjects between groups (p>0.05). Level of TNF-α (p<0.001), deoxypyridinoline (p<0.001) and osteocalcine (p=0.041) was significantly higher in the study group compared to the control group. Osteoprotegerin was lower in BD patients, but the difference was not significant (p>0.05). Urinary deoxypyridinoline/ urinary creatinine ratio in patients with BD was significantly higher than those in control group (p=0.030). Patients had significantly lower BMD comparfed to the control group, except L2-L4 vertebral area (p<0.001, p<0.001, p=0.035, p<0.001, p=0.012, p<0.001, p<0.001 and p=0.111, respectively). No correlation was found between TNF-α and osteoprotegerin. Conclusions: The present study indicated that TNF-α and BMD was negatively correlated with each other and TNF-α had an effect on osteoporotic process in patients with BD. Osteoprotegerin level was not decreased, and not correlated with TNF-α.

PDF

___

1. Kalayciyan A, Zouboulis C. An update on Behçet’s disease. J Eur Acad Dermatol Venereol 2007; 21(1):1-10.
2. Bicer A, Tursen U, Kaya TI, et al. Bone mineral density in patients with Behçet’s disease. Rheumatol Int 2004; 24(6):355-8.
3. Kirnap M, Calis M, Kaya N, Muhtaroglu S. Is the Behcet’s disease a risk factor for osteoporosis and is relation to cytokines? Bratisl Lek Listy 2010; 111(6):340-4.
4. Tekin NS, Ozdolap S, Sarikaya S, Esturk E, Gumustas S. Bone mineral density and bone turnover markers of patients with Behçet’s disease. J Eur Acad Dermatol Venereol 2007; 21(1):25-9.
5. Schett G, Redlich K, Hayer S, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factortransgenic mice. Arthritis Rheum 2003; 48(7):2042-51.
6. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008; 42(3):467-75.
7. Yuksel S, Samli H, Colbay M, et al. Increased serum osteoprotegerin levels associated with decreased bone mineral density in familial Mediterranean fever. Tohoku J Exp Med 2009; 217(4):321-7.
8. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003; 12(4):1-15.
9. Sophie R, Philippe O. Bone loss: factors that regulate osteoclast differentiation-an update. Arthritis Res 2000; 2(6):451-6.
10. Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, IL-2, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm 2000; 11(2):87-93.
11. Gürsoy S, Adam M. Romatoid artritli olguların fonksiyonel durumu, hastalık süresi, esh, kmy değeri, osteokalsin ve crp düzeyi arasında korelasyonların varlığının araştırılması. Turk J Rheumatol 2000; 15(3):167-71.
12. Sarikaya S, Basaran A, Tekin Y, Ozdolap S, Ortancil O. Is osteoporosis generalized or localized to central skeleton in ankylosing spondylitis? J Clin Rheumatol 2007; 13(1):20- 4.
13. Mihaljević I, Mudri D, Smolić R, Smolić M, Tucak-Zorić S. Biochemical bone turnover markers: significance in patients with osteoporosis. Coll Antropol 2009; 33(2):21-4.
14. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization taskforce for osteoporosis. Osteoporos Int 1999; 10(4):259-64.
15. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. The European Foundation for Osteoporosis and Bone Disease: Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997; 7(4):390-406.
16. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumor necrosis factor- alpha and nitric oxide level in patients with Behçet’s disease. Ann Acad Med Singapore 2004; 33(5):596-9.
17. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009; 88(1):1-17.
18. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2):309-19.
19. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, et al. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 2001; 44(6):1254-60.